Launches cloud-based version of solution to target mid-size clients in life sciences.
Not much is heard or read about Sun Pharma's media-shy owner.
Besides foreign flows, corporate earnings and US Federal Reserve chief Janet Yellen's testimony to the nation's legislature are also likely to impact investor sentiment.
Hit by the new drug pricing policy and regulatory interventions, growth rate of the Rs 72,069-crore Indian pharmaceutical market has slowed down to 9.8 per cent in 2013 as compared to 16.6 per cent in 2012, says a report.
Markets ended their lowest close in 2015 on fears of FII outflows as the US Fed may hike rates.
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
The 30-share Sensex provisionally ended up 112 points at 28,555 and the 50-share Nifty closed 24 points higher at 8,561 after hitting a record high of 8,626.95.
Top losers are Sun Pharma, Bajaj Auto, L&T, ITC, Hero Moto.
Combined net profit estimated to grow 14.6% year-on-year, against a 5.7% decline in the Dec 2015 quarter
Sahil Vachani fuels Analjit Singh's new business initiatives
On October 2, a legislature committee wrote letters to the 14 companies, initiating an investigation and seeking details about recent price increases in several generic products available in the American market.
Among the index heavyweights, Reliance Industries ended down 1.9% while mortage lender HDFC eased 0.2%. FMCG major ITC ended down 1.3%.
The year saw 30 QIP deals raising over $5 billion and 35 IPOs.
This is to take head on big American pharmaceutical giants, which in the recent past had launched a strong anti-India campaign against efforts of such companies to provide affordable health care not only to people in India, but also in the third world countries.
The move assumes significance because a go-ahead from the US Food and Drug Administration for the new unit in Visakhapatnam is likely to give a huge boost to the company's revenues in upcoming quarters.
Sensex sinks into red at close on growth concerns.
US will remain a growth driver, with launches & existing portfolios set to result in 15% growth for FY15.
Nifty50 surged 87 points to end at 8,157, highest closing levels since Oct 29, 2015.
Wockhardt MD Murtaza Khorakiwala said his firm had responded to the FDA's observations but declined to give details.
Post-elections, the pace is expected to be greater for inbound deals, which have been largely pushed back for many months now for want of better clarity on the policy stance of new government, experts said.
Positive cues from Asian peers also uplifted the sentiment.
The Sensex ended down 251 points at 27,351 and the Nifty shed 65 points to close at 8,228.
Samvat 2070 was a great year for top Indian conglomerates in the stock markets.
Sensex, Nifty put up a good show in closing trade.
S&P upgraded India's credit outlook to 'stable' from 'negative' earlier.
The 30-share Sensex ended down 224 points at 28,442 and the 50-share Nifty ended down 101 points at 8,606.
The 30-share Sensex ended up 165 points at 29,044 and the 50-share Nifty gained 54 points to close at 8,834.
The top gainers on the Sensex were Cipla, Bharti Airtel, Maruti Suzuki, Hero Moto & Sesa Sterlite.
The latest price revision includes mostly cardiovascular drugs, anti-bacterials, anti-herpes, contraceptives and gastrointestinal medicines
Few top honchos of India Inc did very well in 2014.
The 30-share Sensex ended down 604 points at 28,845 and the 50-share Nifty ended down 181 points at 8,757. The Bank Nifty ended down 602 points at 19,146.
The big companies too are responsible for the sub-standard drugs in the market.
The babas' vote banks and the politicians' greed for en bloc votes, is the curse of Punjab and Haryana.
Large and small businesses alike have delivered low-key performances.
Mergers are not just about balance sheets or marketing synergies; they are also about those who make the synergies real.
India is failing to take advantage of its important ally, Japan as much as it should, notes Mihir S Sharma.
The broader markets ended negatively with mid-caps and small-caps shedding 0.5 per cent on the BSE.
The S&P BSE Sensex has rallied about 28 per cent in 2014, after formation of a stable government at the Centre.
FDI in brownfield investment has resulted in acquisition of domestic drug-manufacturing firms by multinational companies.
Inspections only in domestic authorities' presence, visiting US drug regulator told
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances